Investigating new treatments for Alzheimer's disease targeting tau protein.
Official title: The Alzheimer's Disease Tau Platform Clinical Trial
Funded at University of California, San Francisco · NIH-10932876 · Data updated 2026-11-12
This study is looking at new treatments that target a protein called tau, which is connected to Alzheimer's disease, to see how well they work and if they are safe for people with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $29,813,375 |
| NIH project number | 5R01AG078457-02 |
| Project ID | NIH-10932876 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals in the early stages of Alzheimer's disease, particularly those with preclinical or prodromal symptoms.
✕Less likely to help
Patients with advanced Alzheimer's disease or those without tau pathology may not benefit from this research.
What this research studies
This research focuses on developing and testing new therapies aimed at tau protein, which is linked to the severity of Alzheimer's disease (AD). The trial will evaluate multiple tau-directed therapies, both alone and in combination with anti-amyloid treatments, to assess their safety and effectiveness. By utilizing advanced biomarkers and imaging techniques, the study aims to accelerate the clinical development of these therapies. Patients will be monitored for their response to treatment using various biological markers, providing insights into the effectiveness of the therapies being tested.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease, potentially improving patient outcomes and quality of life.
How similar studies have gone: Previous research has shown promise in targeting tau protein for Alzheimer's treatment, indicating that this approach could lead to significant advancements in therapy.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Boxer, Adam L. — University of California, San Francisco
- Study coordinator: Boxer, Adam L.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.